Cesare Pane

Mr. Cesare Pane

Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2026 in Infectious Agents and Cancer
Verified
Journal Article
Open access
PDF file
MCMarco Cascella
Marco Cascella
CPCesare Pane
Cesare Pane
MPMarcello Di Pumpo
Marcello Di Pumpo
ESEnrico Sebastiani
Enrico Sebastiani
MBMartino Bussa
Martino Bussa
VGVincenza Granata
Vincenza Granata
Digital health technologies (DHTs), including digital therapeutics (DTx), are revolutionizing patient care by enabling the prevention, management, and trea

28 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MCMarco Cascella
Marco Cascella
CPCesare Pane
Cesare Pane
MPMarcello Di Pumpo
Marcello Di Pumpo
ESEnrico Sebastiani
Enrico Sebastiani
MBMartino Bussa
Martino Bussa
VGVincenza Granata
Vincenza Granata
Digital health technologies (DHTs), including digital therapeutics (DTx), are revolutionizing patient care by enabling the prevention, management, and treatment of medical conditions. These tools comprise care delivery mobile applications, wearable devices, and cloud platforms for capturing real-time data and enabling remote monitoring. DTx also encompasses artificial intelligence (AI) and machine learning algorithms, as well as AI agents and digital twins (DTs) for clinical decision-making and predictive analytics. Evidence supports the effectiveness of DHT strategies across different clinical fields. For example, wearable and remote patient monitoring technologies enable continuous assessment and personalized feedback in cardiology and neurology. Additionally, AI-enabled devices are mostly implemented for continuous monitoring of glucose levels. However, several key challenges remain. Persistent gender and social biases in datasets and algorithms raise ethical concerns, particularly for underrepresented groups and pediatric populations. Mitigation strategies include regulatory frameworks, explainable AI, and trustworthy AI ecosystems. This narrative review synthesizes current evidence, highlights implementation barriers, and proposes recommendations to enhance inclusivity, interoperability, and real-world evaluation of these technologies. Applications of DHT in animals within the one digital health framework are also discussed.

6 June 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
STSara Troisi
Sara Troisi
CPCesare Pane
Cesare Pane
LMLetizia Masi
Letizia Masi
Filippo BiamonteFilippo Biamonte
Filippo Biamonte
DSDomenico Scannone
Domenico Scannone
FSFRANCO SCALDAFERRI
FRANCO SCALDAFERRI
Background/Objectives: Butyrate, a microbiota-derived short-chain fatty acid, plays a central role in intestinal homeostasis, yet its concentration-dependent effects on human inflamed mucosa remain poorly defined. This study investigates the dose-dependent impact of butyrate on inflammatory signaling and epithelial architecture in ex vivo intestinal biopsies from patients with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). Methods: Intestinal biopsies from six IBD patients (four UC, two CD) were cultured ex vivo for 24 h with calcium butyrate (5, 10, 100 mM). Cytokine secretion was analyzed by multiplex immunoassay, total protein release was quantified, and glandular morphology was assessed by stereological analysis. Results: Butyrate was associated with a dose-dependent reduction in pro-inflammatory cytokines-including TNF-α, IFN-γ, IL-6, and IL-17-in both inflamed and non-inflamed tissue. Non-linear responses were observed for specific mediators, such as IP-10, which displayed a biphasic pattern in inflamed UC biopsies. Notably, UC and CD biopsies exhibited distinct response profiles: UC samples showed marked cytokine modulation, including reduction in IL-15, whereas CD samples, evaluated at 5 and 10 mM, showed limited modulation across conditions. A trend toward reduced total protein secretion was observed in diseased UC biopsies following butyrate exposure. Stereological analysis revealed preservation of glandular area at 5 mM, reduction at 10 mM, and extensive tissue disruption at 100 mM precluding structural evaluation. Conclusions: In this pilot study, butyrate exerts dose-dependent and disease-specific effects in human IBD mucosa within a narrow therapeutic window. These exploratory findings suggest that dose-optimized strategies for butyrate-based interventions may be particularly relevant in UC, although larger confirmatory studies are needed.

10 September 2026 in Cells
Verified
Journal Article
Open access
PDF file
CPCesare Pane
Cesare Pane
PPPierluigi Puca
Pierluigi Puca
MMMiriam Di Mattia
Miriam Di Mattia
STSara Troisi
Sara Troisi
MKMarianna Kashyrina
Marianna Kashyrina
APAlfredo Papa
Alfredo Papa
Short bowel syndrome is a rare and clinically heterogeneous condition resulting from extensive intestinal resections or functional impairment, leading to malabsorption, fluid and electrolyte losses, and potential progression to intestinal failure requiring long-term parenteral nutrition. The long-term outcome of SBS is largely determined by intestinal adaptation, a progressive physiological response involving epithelial remodeling, intestinal stem cell expansion, lineage-specific proliferation, vascular remodeling, and the activity of trophic mediators—most notably glucagon-like peptide-2 (GLP-2)—whose clinical relevance is exemplified by teduglutide. Despite significant therapeutic advances, the mechanisms underlying adaptation remain incompletely understood, and preclinical models are essential tools for addressing this gap. In vitro systems—including Caco-2 epithelial cultures, intestinal organoids and enteroids, and tissue-engineered intestinal constructs—enable pathway-specific mechanistic investigation and hold promise as regenerative platforms. Murine surgical models of small bowel resection and ileocecal resection provide an integrated in vivo context for dissecting cellular and molecular mechanisms of adaptation. Large animal models, particularly minipig platforms, offer anatomical and physiological proximity to humans required for translational and therapeutic evaluation. In this narrative review, we provide an updated overview of these preclinical systems, critically examining their respective strengths, limitations, and translational relevance to advance the understanding of intestinal adaptation and inform the development of more effective therapeutic strategies for SBS (graphical abstract).